Statements

COVID-19 Supply Situation

We continue to monitor the global COVID-19 situation. As of June 1, 2020, the supply, manufacturing and distribution of Astellas products in the United States are not impacted, and patients will continue to be able to receive all approved US medicines, including our oncology and transplantation medicines, without interruption related to COVID-19. As the COVID-19 situation continues to evolve, Astellas remains focused on protecting our ability to manufacture and supply safe and effective medicines for patients who need them. Please direct any additional questions to our Medical Information line at 800-727-7003.